SEARCH

SEARCH BY CITATION

References

  • The MI Procedure. http://support.sas.com/rnd/app/papers/miv802.pdf.
  • The MIANALYZE Procedure. http://support.sas.com/rnd/app/papers/mianalyzev802.pdf.
  • Brennan AT, Maskew M, Ive P et al. (2013) Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. Journal of the International AIDS Society 16, 18794.
  • Bygrave H, Ford N, Van CG et al. (2011) Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years. Journal of Acquired Immune Deficiency Syndromes 56, e75e78.
  • Chi BH, Mwango A, Giganti M et al. (2010) Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. Journal of Acquired Immune Deficiency Syndromes 54, 6370.
  • Clinton Foundation (2009) Antiretroviral (ARV) Price List. http://www.givewell.org/files/DWDA%202009/Interventions/WJCF-ARVPrices-2009.pdf.
  • Domingos H, Cunha RVD, Paniago AMM, Martins DM, Elkhoury EB & Souza ASD (2009) Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Brazilian Journal of Infectious Diseases 13, 130136.
  • Druyts E, Dybul M, Kanters S et al. (2013) Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS 27, 417425.
  • Ferradini L, Laureillard D, Prak N et al. (2007) Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 15, 22932301.
  • Fine JP & Gray RJ (1999) A proportional hazards model for the sub distribution of a competing risk. JSTOR 94, 496509.
  • Fox MP, Brennan A, Maskew M, MacPhail P & Sanne I (2010) Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Tropical Medicine and International Health 15, 405413.
  • Fox MP, Maskew M, Macphail AP et al. (2013) Cohort profile: The Themba Lethu Clinical Cohort, Johannesburg, South Africa. International Journal of Epidemiology 42, 430439.
  • Gallant JE, Staszewski S, Pozniak AL et al. (2004) Efficacy and safety of Tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292, 191201.
  • Gilks CF, Crowley S, Ekpini R et al. (2006) The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 5, 505510.
  • Global HIV/AIDS response (2011) Epidemic update and health sector progress towards Universal Access. Progress Report 2011.
  • van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF & Reid T (2010) Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Transactions of the Royal Society of Tropical Medicine and Hygiene 104, 148153.
  • Maini MK, Cilson RJC, Chavda N et al. (1996) Reference ranges and sources of variability of CD4 counts in HIV seronegative women and men. Genitourinary Medicine 72, 2731.
  • McComsey G & Lonergan JT (2004) Mitochondrial dysfunction: patient monitoring and toxicity management. Journal of Acquired Immune Deficiency Syndromes 37 (Suppl. 1), S30S35.
  • Medecins Sans Frontieres (2008) Untangling the web of antiretroviral price reductions, 11th edn. [March 2, 2009]. http://www.msfaccess.org.
  • Meyer-Rath G, Brennan A, Long L, Rosen S & Fox MP (2013) National ART Cost Model South Africa. Health Economics and Epidemiology Research Office, Johannesburg, South Africa.
  • Murphy R, Sunpath H, Kuritzkes DR, Venter F & Gandhi RT (2007) Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. Journal of Infectious Diseases 196 (Suppl. 3), S449S456.
  • National Department of Health (2004) National Antiretroviral Treatment Guidelines. Jacana Publishers, Johannesburg, Republic of South Africa.
  • National Department of Health (2010) The South African Antiretroviral Treatment Guidelines, Republic of South Africa [http://www.doh.gov.za/docs/factsheets/guidelines/art.pdf].
  • National Department of Health (2011) Circular on new criteria for initiating adults on ART at CD4 count of 350 cells/μl and below, National Department of Health, Johannesburg, Republic of South Africa.
  • Nelson MR, Katlama C, Montaner JS et al. (2007) The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21, 12731281.
  • Rosen S, Long L, Fox M & Sanne I (2008) Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. Journal of Acquired Immune Deficiency Syndromes 48, 334344.
  • Rubin DB (1987) Multiple imputation for Nonresponse in Surveys. John Wiley & Sons, New York.
  • Scherzer R, Estrella M, Li Y et al. (2012) Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 26, 867875.
  • Southern African HIV Clinicians Society (SAHIVSOC). Stock Outs in South Africa – A National Crisis. http://stockouts.org/uploads/3/3/1/1/3311088/stock_outs_a_national_crisis.pdf
  • Statistics South Africa (2005) Mortality and causes of death in South Africa, 1997–2003. Findings from death notification. P0309.3.
  • Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N (2007) Adverse effects of highly active antiretroviral therapy in developing countries. Clinical Infectious Diseases 45, 10931101.
  • Timaeus I, Dorrington R, Bradshaw D & Nannan N (2002) Mortality trends in South Africa 1985–2000: From apartheid to AIDS. South African Medical Research Council, Cape Town.
  • UNAIDS (2009) The Global Economic Crisis and HIV Prevention and Treatment Programmes: Vulnerabilities and Impact. UNAIDS, Geneva, Switzerland.
  • U.S. Food and Drug Administration (2001) Approval letter VIREAD. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2001/21356ltr.pdf
  • Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ & Hoffmann CJ (2013) Comparison of tenofovir, Zidovudine, or Stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study. PLoS One 8, e64459.
  • World Health Organization (2007) Addendum to 2006 WHO Guidelines on Antiretroviral Therapy for HIV Infection in Adults and Adolescents. World Health Organization, Geneva.
  • World Health Organization (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach – 2010 Revision. World Health Organization, Geneva, Switzerland.